Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT00679042 on ClinicalTrials.gov · last registry update 2026-04-06

A small phase 3 — 21 participants, against a typical 424. The sponsor logged completion for 19 July 2017. Primary outcome, as filed: Treatment Emergent Adverse Events. exenatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: ACTIVE_NOT_RECRUITING
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: CellTrans Inc.
Sponsor type: Industry
Enrollment: 21
Started: 2007-09-05
Primary completion: 2017-07-19 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Treatment Emergent Adverse Events

Conditions studied

Type 1 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.